LMNL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Sep 2023 @ 15:59):

Stats
Today's Volume	5 055.00
Average Volume	23 725.00
Market Cap	27.62M
EPS	$0 ( 2024-03-13 )
Next earnings date	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.245
ATR14	$0.0410 (0.48%)

Volume Correlation

Long: 0.13 (neutral)

Short: -0.52 (weak negative)

Signal:(77.099) Neutral

Liminal BioSciences Inc Correlation

10 Most Positive Correlations
BCLI	0.848
GOODM	0.836
AEYE	0.833
BUFF	0.831
ACHV	0.828
RDWR	0.824
TBLD	0.819
CMPR	0.819
BOSC	0.815
TAYD	0.814

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Liminal BioSciences Inc Correlation - Currency/Commodity

0.61
( weak )

0.53
( weak )

0.68
( moderate )

-0.68
( moderate negative )

0.42
( neutral )

-0.31
( neutral )

Liminal BioSciences Inc Financials

Annual	2022
Revenue:	$401 000
Gross Profit:	$401 000 (100.00 %)
EPS:	$-9.32

Q2	2023
Revenue:	$112 000
Gross Profit:	$112 000 (100.00 %)
EPS:	$-2.94

Q1	2023
Revenue:	$136 000
Gross Profit:	$136 000 (100.00 %)
EPS:	$-2.46

Q4	2022
Revenue:	$241 000
Gross Profit:	$241 000 (100.00 %)
EPS:	$-1.540

Financial Reports:

No articles found.

Liminal BioSciences Inc

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.